Cyclacel Presents Updated Survival Data From the Pilot Study and Lead-In Phase of Seamless Phase 3 Study at the 2012 ASH Annual Meeting

[at noodls] – Median Overall Survival is 238 days, or Approximately 8 Months, and 1-Year Survival is 35% With an Overall Response Rate of 41% in Elderly Patients With Newly Diagnosed AML BERKELEY HEIGHTS, N.J., Dec. … more

View todays social media effects on CYCCP

View the latest stocks trending across Twitter. Click to view dashboard

See who Cyclacel is hiring next, click here to view